^
Association details:
| Biomarker: | KIT exon 11 mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Excerpt:
...Participants in Cohort A must have evidence of activation mutations in exon 11 of KIT in their tumors....
Trial ID:
Source:
Title:
PHASE 2 STUDY OF PONATINIB IN ADVANCED GASTROINTESTINAL STROMAL TUMORS: EFFICACY, SAFETY, AND IMPACT OF LIQUID BIOPSY AND OTHER BIOMARKERS
Published date:
01/28/2022
Excerpt:
Forty-five patients enrolled (30 KIT ex11-positive and 15 KIT ex11-negative); median follow-up was 14.7 and 13.6 months, respectively, as of August 1, 2016. Sixteen-week CBR was 36% (KIT ex11-positive; primary endpoint) and 20% (KIT ex11-negative)….Ponatinib demonstrated activity in advanced GIST, particularly in KIT ex11-positive disease.
DOI:
10.1158/1078-0432.CCR-21-2037
Source:
Title:
Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study.
Excerpt:
Cohorts were enrolled based on presence (A) or absence (B) of KIT exon 11 mutations...Cohort A CBR was 37% (10/27); ORR 7% (2/27). Best responses: PR 2; SD 16. Median PFS/OS: 4.3 mo/15.0 mo….Ponatinib has clinical activity in advanced GIST pts after TKI failure, particularly pts with KIT exon 11 mutation.
DOI:
10.1200/jco.2015.33.15_suppl.10535
Trial ID:
